Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031750 | 1.00 | DPP4 (0.47) | DPP4DPP8DPP7PAX8FAP | |
| SCHEMBL1035824 | 0.85 | DPP4 (0.52) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL1035823 | 0.85 | DPP4 (0.52) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL7183450 | 0.85 | DPP4 (0.52) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL27677392 | 0.82 | DPP4 (0.40) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL9637204 | 0.80 | DPP4 (0.41) | DPP4DPP8DPP7PAX8DPP9 | |
| SCHEMBL9637205 | 0.80 | DPP4 (0.41) | DPP4DPP8DPP7PAX8DPP9 | |
| SCHEMBL1035791 | 0.80 | CTSC (0.40) | DPP4DPP8DPP7PAX8FAP | |
| SCHEMBL8502890 | 0.79 | DPP4 (0.40) | DPP4DPP8DPP7PAX8CTRB1 | |
| SCHEMBL29010822 | 0.79 | SLC7A5 (0.44) | CTSCSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1043631-A | The compositions that is used for the sustained release polypeptide | MONSANTO CO (US) | 1990-07-11 | — | — | CN | claimed |
| EP-2277884-B1 | ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-23 | — | — | EP | disclosed |
| US-9115165-B2 | Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-08-25 | — | — | US | disclosed |
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2011-09-15 | — | — | US | disclosed |
| EP-2277884-A1 | ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-01-26 | — | — | EP | disclosed |
| EP-1267898-A4 | BILE ACID CONTAINING PRODRUGS WITH ENHANCED BIOAVAILABILITY | UNIV MARYLAND (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20030212051-A1 | Bile acid containing prodrugs with enhanced bioavailabilty | UNIVERSITY OF MARYLAND, BALTIMORE | 2003-11-13 | — | — | US | disclosed |
| EP-1267898-A2 | BILE ACID CONTAINING PRODRUGS WITH ENHANCED BIOAVAILABILITY | University of Maryland, Baltimore (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001076531-A2 | BILE ACID CONTAINING PRODRUGS WITH ENHANCED BIOAVAILABILITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2001-10-18 | — | — | WO | disclosed |
| US-5672357-A | Method and device for implantation of large diameter objects in bovines | MONSANTO COMPANY (US) | 1997-09-30 | — | — | US | disclosed |
| US-5670162-A | Method and device for implantation of large diameter objects in bovines | MONSANTO COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0773792-A1 | COMBINATION TREATMENT AS ANIMAL GROWTH PROMOTER CONTAINING BOVINE SOMATOTROPIN AND AN ESTROGENIC AGENT | MONSANTO COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| US-5595752-A | SOMATOTROPIN | MONSANTO COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| WO-1996001123-A1 | COMBINATION TREATMENT AS ANIMAL GROWTH PROMOTER CONTAINING BOVINE SOMATOTROPIN AND AN ESTROGENIC AGENT | MONSANTO COMPANY (US) | 1996-01-18 | — | — | WO | disclosed |
| EP-0403032-B1 | METHOD FOR PROLONGED RELEASE OF SOMATOTROPIN | MONSANTO COMPANY (US) | 1993-08-11 | — | — | EP | disclosed |
| EP-0283458-B1 | SOMATROPIN PROLONGED RELEASE | MONSANTO COMPANY (US) | 1992-06-24 | — | — | EP | disclosed |
| EP-0403032-A2 | Method for prolonged release of somatotropin | MONSANTO COMPANY (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0374120-A2 | Comosition for controlled release of polypeptides | MONSANTO COMPANY (US) | 1990-06-20 | — | — | EP | disclosed |
| US-4863736-A | GROTHW REGULATORS, MILK PRODUCTION | MONSANTO COMPANY (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0283458-A2 | Somatropin prolonged release | MONSANTO COMPANY (US) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | DHPS, TBCA, ANTXR2 | DPP4 3343/4885DPP8 3954/4885DPP7 3349/4885 |
| US-20030212051-A1 | Bile acid containing prodrugs with enhanced bioavailabilty | SLC10A2, SLC10A1, NR1H4 | DPP4 321/4885DPP8 238/4885DPP7 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.